Surrogate outcomes and fast-track drug approval
Boletín de Información Farmacoterapéutica de Navarra · 2025
DOI: 10.54095/bitn20253201en ↗Kurz gefasst
Fachartikel in der Zeitschrift Boletín de Información Farmacoterapéutica de Navarra, 2025. Verfasst von Luis Carlos Saiz Fernández.
Abstract (Originalsprache)
INTRODUCTION When investigating drug efficacy, surrogate variables are becoming increasingly important. They are simpler and quicker to obtain than clinical variables, but only indirectly related to the effect of interest. The aim of this bulletin is to describe and reflect on the implications of adopting surrogate endpoints and accelerated approval strategies in drug evaluation. METHODS A literature search was conducted on 30/04/2024 in MedLine, The Cochrane Library, websites of regulators and health technology assessment agencies, and other sources, focusing on the term ‘surrogate outcome’. CONCLUSIONS Surrogate outcomes require adequate validation to prove their usefulness. However, health authorities accept variables with progressively lower standards. Accelerated approvals require confirmatory studies that are often not completed. HIV viral load or blood pressure are examples of adequately validated variables. In contrast, inconsistencies are identified in variables used in the approach to cancer, dementia, osteoporosis and infectious or cardiovascular diseases. Premature access to pharmacological therapies may result in a higher incidence of adverse reactions with little scope for implementing harm mitigation strategies. The abandonment of clinical trials in favour of predictive or observational designs compromises the quality of the evidence obtained.
Zitieren
APA
Fernández, L. C. S. (2025). Surrogate outcomes and fast-track drug approval. Boletín de Información Farmacoterapéutica de Navarra. https://doi.org/10.54095/bitn20253201en
Vancouver
Fernández LCS. Surrogate outcomes and fast-track drug approval. Boletín de Información Farmacoterapéutica de Navarra. 2025. doi:10.54095/bitn20253201en
BibTeX
@article{Fernndez2025,
author = {Fernández, Luis Carlos Saiz},
title = {Surrogate outcomes and fast-track drug approval},
journal = {Boletín de Información Farmacoterapéutica de Navarra},
year = {2025},
doi = {10.54095/bitn20253201en}
}
EUVIMED